Title : Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.

Pub. Date : 2021 Jul 20

PMID : 34372612






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment with the JAK inhibitor ruxolitinib suppressed STAT5 phosphorylation and expression of the key anti-viral response protein MX1 and enhanced the anti-TCL activity of Reolysin in both HTLV-1-positive and negative cells. ruxolitinib signal transducer and activator of transcription 5A Homo sapiens